Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer at ASCO GU 2016 in San Francisco.

Advertisement Single Below Content

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer

Related Posts

Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani

Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD

FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia